Results 31 to 40 of about 34,967 (216)

Rivaroxaban in atrial fibrillation cardioversion: an update [PDF]

, 2019
Carlo Lavalle, Martina Straito, Annalisa Caroli, Agostino Piro, Giuseppe Giunta, Marco Valerio Mariani, Francesco FedeleDepartment of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, “Sapienza” University ...
Giunta G, Straito M, Lavalle C, Mariani MV, Lavalle C., Giunta G., Piro A., Fedele F, Mariani M. V., Piro A, Caroli A., Fedele F., Caroli A, Straito M.   +13 more
core   +1 more source

The Effect of Rivaroxaban on CYP4F2 and Transcription Factors’ Activity in HUVECs

Applied Sciences, 2021
Interindividual variabilities between patients taking the anticoagulant rivaroxaban are a result of hepatic metabolism by CYP 450 enzymes. The objective of this study was to evaluate the impact of rivaroxaban on CYP4F2 and transcription factors’ activity
Ieva Ciapiene, Vacis Tatarunas, Agne Giedraitiene, Vaidotas Zvikas, Valdas Jakstas, Audrone Veikutiene, Ugne Meskauskaite, Ugne Venckyte, Audrius Pukalskas, Vaiva Lesauskaite   +9 more
doaj   +1 more source

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

Pharmaceutics
This study aimed to investigate the impact of the drug–drug interaction between rivaroxaban and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation (NVAF), focusing on pharmacokinetic and pharmacodynamic (PK/PD) aspects.
Huamin Ding, Zi Wang, Jia Wang, Yao Yao, Chi Zhang, Houwen Lin, Yong Zhou, Zhichun Gu, Qianzhou Lv, Xiaoye Li   +9 more
doaj   +1 more source

Impact of rivaroxaban on point-of-care assays [PDF]

, 2017
BACKGROUND: Point-of-care testing (POCT) is regularly used to assess haemostasis in various clinical settings. The impact of rivaroxaban on those POCT is still elusive.
Hans Stricker, Mendez, Adriana, Schmid, Pirmin, Wolfgang Korte, Walter A. Wuillemin, Adriana Mendez, Michael Nagler, Studt, Jan-Dirk, Stricker, Hans, Alberio, Lorenzo, Pirmin Schmid, Dimitrios A. Tsakiris, Angelillo-Scherrer, Anne, Lorenzo Alberio, Tsakiris, Dimitrios A, Anne Angelillo-Scherrer, Lars M. Asmis, Pierre Fontana, Jan-Dirk Studt, Asmis, Lars, Asmis, Lars M, Nagler, Michael, Fontana, Pierre, Korte, Wolfgang, Wuillemin, Walter A   +24 more
core   +1 more source

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement [PDF]

, 2020
BACKGROUND Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.
Makkar, Raj R, Giustino, Gennaro, Zazula, Ana, Søndergaard, Lars, Wildgoose, Peter, Tchétché, Didier, Möllmann, Helge, Welsh, Robert C., Kini, Annapoorna, Curzen, Nicholas, Mack, Michael, Welsh, Robert C, Thomitzek, Karen, Volkl, Albert A, De Backer, Ole, GALILEO, Moellmann, Helge, Dangas, George D., Schäfer, Ulrich, Guimaraes, Ana H. C., van Amsterdam, Ronald G M, Tijssen, Jan G.P., Sondergaard, Lars, van Amsterdam, Ronald G. M., Schaefer, Ulrich, Moreno, Raúl, Gullestad, Lars, Guimarães, Ana H C, Vranckx, Pascal, Guimarães, Ana H.C., GALILEO Investigators, Dangas, George D, Kreuzpointner, Robert, van Amsterdam, Ronald G.M., Tijssen, Jan G P, Woehrle, Jochen, Windecker, Stephan, Volkl, Albert A., Herrmann, Howard C., Baldus, Stephan, von Lewinski, Dirk, Seeger, Julia, Makkar, Raj R., Gilard, Martine, Tijssen, Jan G. P., Wöhrle, Jochen, Herrmann, Howard C, Valgimigli, Marco, Mehran, Roxana   +48 more
core   +2 more sources

Impact of parameter settings on the estimation of drug exposure with the individualized dispensing patterns method

British Journal of Clinical Pharmacology, EarlyView.
Aim To assess the impact of parameter settings when using the individualized dispensing patterns (IDP) method to estimate exposure duration from dispensing data. Methods We conducted a cohort study using a 2% representative sample of the French healthcare insurance database from 2013 to 2022.
Laëtitia Gosselin, Clara Lévy, Noémie Sève, Thierry Blanchon, Marianne Sarazin, Louise Rossignol, Maryse Lapeyre‐Mestre, Nathanaël Lapidus, Olivier Steichen   +8 more
wiley   +1 more source

Rivaroxaban Attenuates the Cardiovascular PAR1-Related Inflammation, Fibrosis and Atherogenicity in Experimental Hypertensive/ Hypercholesterolemia Rat Model [PDF]

The Egyptian Journal of Histology
Introduction: Hypertension and hypercholesterolemia serve as a predisposing component for cardiovascular disorders. As an oral anticoagulant, Rivaroxaban is used to preclude and eliminate venous thrombosis, atrial fibrillation and coronary artery ...
Hanan Shamardl, Eman Hussien, Marwa Sofi, Sawsan Sadik   +3 more
doaj   +1 more source

Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation

CJC Open, 2021
Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation
Jiaming (Calvin) Liang, MD, MSc, Karanvir Raman, BBA, Siu Him Chan, MD, A. Yashar Tashakkor, MD   +3 more
doaj   +1 more source

Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies, Elin Haf Davies, Dyfrig A. Hughes   +2 more
wiley   +1 more source

Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage [PDF]

, 2018
Information about Rivaroxaban plasma levels (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking ...
Thilemann, Sebastian, Kägi, Georg, Sandor, Peter S, Engelter, Stefan T, Cappellari, Manuel, Emmanuel De Maistre, De Marchis, Gian Marco, Manuel Cappellari, Susanne Wegener, Berge, Eivind, Sebastian Thilemann, De Maistre, Emmanuel, Nils Peters, Béjot, Yannick, Schädelin, Sabine, Stefan T. Engelter, Eivind Berge, Gian Marco De Marchis, Zini, Andrea, Monika Kapauer, Zedde, Marialuisa, David Werring, Alexandros A. Polymeris, null null, Guillaume Turc, Andrea Zini, Andreas Luft, Marcel Arnold, Kapauer, Monika, Patrik Michel, Seiffge, David J, Traenka, Christopher, Arnold, Marcel, Turc, Guillaume, Marialuisa Zedde, Fischer, Urs, Dimtrios A. Tsakiris, Sabine Schädelin, Cordonnier, Charlotte, Werring, David, Urs Fischer, Jochen Vehoff, Luft, Andreas, David J. Seiffge, Michel, Patrik, Ilaria Maestrini, Charlotte Cordonnier, Sirimarco, Gaia, Tsakiris, Dimitrios A, Bonati, Leo H, Leo H. Bonati, Vehoff, Jochen, Maestrini, Ilaria, Georg Kägi, Peters, Nils, Yannick Béjot, Gaia Sirimarco, Philippe A. Lyrer, Tsakiris, Dimtrios A, Lyrer, Philippe A, Polymeris, Alexandros A, Gilles Rodier, Rodier, Gilles, Christopher Traenka, Wegener, Susanne, Peter S. Sandor   +65 more
core   +1 more source